FYB Formycon AG
19.10EUR+4.37%Mkt Cap: 366.91M $P/E: —Today
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular …
Industry Peers
Biotechnology$127.85BUSDP/E 29.4
$75.86BUSD
$75.69BUSDP/E 18.2
$57.51BUSDP/E 35.1
$55.24BUSDP/E 36.1
$44.29BUSD
$41.63BUSDP/E 17.7
$40.51BUSDP/E 63.9
$33.03BUSDP/E 30.7
$29.40BUSDP/E 38.3
$25.80BUSD
$24.34BUSD
$24.27BUSD
$23.37BUSDP/E 14.7
$21.61BUSDP/E 29.3
$21.69BUSDP/E 27.4
$15.30BUSDP/E 16.1
$14.99BUSDP/E 17.8
$14.47BUSDP/E 18.4
$13.37BUSD
| Headline | Source | Time |
|---|---|---|
Today | ||
Older | ||
BBondGuide | ||
Formycon AG (WBO:FYB) (Q2 2026) Earnings Call Highlights: Revenue Nearly Triples on Strong ... Formycon AG (WBO:FYB) reports a significant revenue surge and improved EBITDA, driven by commercial momentum and strategic partnerships. | ||
BBondGuide | ||